World's Best Scientists 2026 revealed!
Laurence Albiges

Laurence Albiges

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 83 15374 14459 496 470 606 38765

Laurence Albiges publications per year

The chart shows the history of publications by Laurence Albiges between 1999 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Laurence Albiges published across 28 years, from 1999 to 2026, averaging 35.6 papers a year. Output peaked at 232 publications in 2023. 108 of the 997 publications appeared in the last two years.

No. of publications
50 100 150 200
Bar chart. Horizontal axis: year, 1999 to 2026. Vertical axis: number of publications, 0 to 232. Peak 232 publications in 2023. 1999: 1 publication 2000: 0 publications 2001: 0 publications 2002: 0 publications 2003: 0 publications 2004: 0 publications 2005: 1 publication 2006: 1 publication 2007: 1 publication 2008: 1 publication 2009: 3 publications 2010: 6 publications 2011: 12 publications 2012: 26 publications 2013: 23 publications 2014: 25 publications 2015: 55 publications 2016: 49 publications 2017: 45 publications 2018: 46 publications 2019: 48 publications 2020: 73 publications 2021: 78 publications 2022: 60 publications 2023: 232 publications 2024: 103 publications 2025: 99 publications 2026: 9 publications
1999 2026

997 publications in total across all disciplines

View publications per year as a table
Laurence Albiges: publications per year, 1999 to 2026
Year Publications
1999 1
2000 0
2001 0
2002 0
2003 0
2004 0
2005 1
2006 1
2007 1
2008 1
2009 3
2010 6
2011 12
2012 26
2013 23
2014 25
2015 55
2016 49
2017 45
2018 46
2019 48
2020 73
2021 78
2022 60
2023 232
2024 103
2025 99
2026 9
Total 997
Download as CSV

Laurence Albiges publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Laurence Albiges sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 601–620 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 606 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396 606
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Laurence Albiges D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Laurence Albiges sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 82–83 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027 83
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Laurence Albiges is affiliated with the Institut Gustave Roussy in France and has contributed extensively to medical research, particularly in the field of oncology and renal cell carcinoma treatment. Their work spans multiple areas including cancer immunotherapy, molecular biology, and cancer genomics, reflecting a multidisciplinary approach to cancer research.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

More specifically, the subfields they have worked in are:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Molecular Biology
  • Cancer Research
  • Economics and Econometrics

The primary topics Laurence Albiges focuses on include:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research

Laurence Albiges has co-authored with leading experts in the field, frequently collaborating with:

  • Toni K. Choueiri
  • Bernard Escudier
  • Gwénaëlle Gravis
  • Ronan Flippot
  • Brian I. Rini

The researcher publishes regularly in several prominent venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • European Journal of Cancer
  • European Urology Oncology

Significant recent publications by Laurence Albiges include:

  • "Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial," 2020, ESMO Open
  • "European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update," 2022, European Urology

Other relevant notable papers in their field, although authored by collaborators, which are closely related to their research interests, include:

  • "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial," 2020, Nature Medicine
  • "Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma," 2020, Annals of Oncology
  • "Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage," 2020, Science

Best Publications

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Renal cell carcinoma.

    James J. Hsieh;Mark P. Purdue;Sabina Signoretti;Charles Swanton

  • Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

    W. Marston Linehan;Paul T. Spellman;Christopher J. Ricketts;Chad J. Creighton

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

    L. Derosa;L. Derosa;L. Derosa;M.D. Hellmann;M.D. Hellmann;M. Spaziano;D. Halpenny

  • Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

    Gwenaelle Gravis;Jean-Marie Boher;Florence Joly;Michel Soulié

  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Claire L. Vale;Sarah Burdett;Larysa H. M. Rydzewska;Laurence Albiges

  • Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Y. Loriot;D. Bianchini;E. Ileana;S. Sandhu

  • Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

    Robert J. Motzer;Paul B. Robbins;Thomas Powles;Laurence Albiges

  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

    T.K. Choueiri;R.J. Motzer;B.I. Rini;J. Haanen

  • Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

    Jean-Marie Michot;Laurence Albiges;Nathalie Chaput;Veronique Saada

  • Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.

    Aurélie Fluckiger;Aurélie Fluckiger;Romain Daillère;Romain Daillère;Mohamed Sassi;Barbara Susanne Sixt

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • PD-L1 expression in nonclear-cell renal cell carcinoma

    T. K. Choueiri;T. K. Choueiri;A. P. Fay;K. P. Gray;M. Callea

  • Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

    François-Xavier Danlos;Anne-Laure Voisin;Valérie Dyevre;Jean-Marie Michot

  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

    Toni K. Choueiri;Mayer Fishman;Bernard Escudier;David F. McDermott

  • Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.

    G. Curigliano;S. Banerjee;A. Cervantes;A. Cervantes;M.C. Garassino

  • Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

    Marcella Callea;Laurence Albiges;Mamta Gupta;Mamta Gupta;Su-Chun Cheng

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Toni K. Choueiri
Toni K. Choueiri Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Yohann Loriot
Yohann Loriot University of Paris-Saclay
Thomas Powles
Thomas Powles Queen Mary University of London
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Christine Chevreau
Christine Chevreau DuPont (United States)
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring Medicine in the USA, there are a growing number of online degree options that can lead to rewarding healthcare careers. Online programs offer flexibility for working adults and those seeking to advance their education while balancing other commitments.

If you’re interested in healthcare leadership, consider enrolling in cheap mha programs to prepare for management positions. For nurses aiming to reach advanced practice or leadership roles, some of the cheapest bsn to dnp programs offer a direct, affordable pathway from a BSN to a Doctor of Nursing Practice degree.

Aspiring pharmacists now have more options as well. Many online pharmacy schools provide flexible, accredited doctorate programs that can be pursued from anywhere in the country. Meanwhile, those interested in the intersection of technology, data, and healthcare may want to explore online schools for health information management—a field that’s rapidly growing alongside electronic medical record adoption.

With these online healthcare degrees, students can access new career pathways in the medical field and make valuable contributions to the future of healthcare in the USA.

Best Scientists Citing Laurence Albiges

Trending Scientists

Recently Published Articles